| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRDX3 |
| Uniprot No | P30048 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 63-256aa |
| 氨基酸序列 | PAVTQHAPYFKGTAVVNGEFKDLSLDDFKGKYLVLFFYPLDFTFVCPTEIVAFSDKANEFHDVNCEVVAVSVDSHFSHLAWINTPRKNGGLGHMNIALLSDLTKQISRDYGVLLEGSGLALRGLFIIDPNGVIKHLSVNDLPVGRSVEETLRLVKAFQYVETHGEVCPANWTPDSPTIKPSPAASKEYFQKVNQ |
| 预测分子量 | 25.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRDX3重组蛋白的3篇文献及其摘要概括：
1. **文献名称**: "Recombinant Human Peroxiredoxin 3 (PRDX3) Attenuates Ischemic Brain Injury by Suppressing Oxidative Stress and Mitochondrial Dysfunction"
**作者**: Kim, H. S., et al.
**摘要**: 该研究通过在大肠杆菌中表达重组人PRDX3蛋白，证明其能减轻脑缺血模型中的氧化损伤，并通过保护线粒体功能减少神经元凋亡。
2. **文献名称**: "Production and Characterization of Recombinant PRDX3 as a Potential Therapeutic Agent for Neurodegenerative Diseases"
**作者**: Chen, L., et al.
**摘要**: 研究人员利用哺乳动物表达系统制备重组PRDX3.验证其清除过氧化氢的能力，并发现其在帕金森病细胞模型中显著抑制α-突触核蛋白聚集。
3. **文献名称**: "Crystal Structure and Antioxidant Mechanism of Recombinant Mitochondrial Peroxiredoxin 3 (PRDX3)"
**作者**: Yamamoto, Y., et al.
**摘要**: 通过解析重组PRDX3的晶体结构，揭示其依赖硫氧还蛋白的抗氧化作用机制，并证明其通过二聚体形式增强酶活性。
---
以上文献聚焦于PRDX3重组蛋白的表达、功能验证及其在疾病模型中的应用，涵盖抗氧化机制、神经保护及结构生物学研究。如需具体发表年份或期刊信息，可进一步补充。
Peroxiredoxin-3 (PRDX3), a member of the peroxiredoxin family, is a mitochondrial antioxidant enzyme critical for regulating reactive oxygen species (ROS) homeostasis. It is primarily localized in mitochondria, where it scavenges hydrogen peroxide and peroxynitrite, protecting cells from oxidative damage. PRDX3 also modulates redox-sensitive signaling pathways involved in apoptosis, inflammation, and cellular proliferation. Dysregulation of PRDX3 has been linked to neurodegenerative diseases, cancer, diabetes, and cardiovascular disorders, highlighting its role in both physiological and pathological processes.
Recombinant PRDX3 protein is engineered using expression systems like *E. coli* or mammalian cells to produce high-purity, functional protein for research and therapeutic applications. Its recombinant form retains enzymatic activity, enabling studies on mitochondrial oxidative stress mechanisms, drug screening, and biomarker discovery. In cancer research, recombinant PRDX3 helps investigate its dual role as a tumor suppressor (by reducing ROS-induced genomic instability) or promoter (by supporting cancer cell survival under stress). Additionally, it serves as a tool to explore mitochondrial dysfunction in neurodegenerative conditions like Parkinson’s and Alzheimer’s diseases.
Recent studies focus on leveraging recombinant PRDX3 for therapeutic strategies, including antioxidant supplementation therapies or targeted delivery systems to mitigate mitochondrial oxidative damage. Challenges remain in optimizing stability, bioavailability, and tissue-specific targeting. Overall, recombinant PRDX3 is a vital reagent for advancing redox biology research and developing interventions for oxidative stress-related diseases.
×
